FDA Announcements we were waiting on:
CelGro Nerve
Q4 2020 US FDA 510K study commences
CelGro Tendon
Q4 2020 FDA pre-submission meeting
CelGro Dental
Q2 2021 FDA Approval (estimate)
Take your pick. An early approval for Dental being the best, a knock back being the worst in my range of expectations. Its a sad indictment of bio-tech management that I have seen in the last few years that I am leaning towards bad news, despite trying to remain rational. Just been roasted that many times by companies with great products and poor management.
Ann: Pause in Trading, page-16
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.5¢ |
Change
0.015(3.33%) |
Mkt cap ! $96.40M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 46.5¢ | 45.0¢ | $74.42K | 164.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5949 | 46.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.0¢ | 70525 | 5 |
View Market Depth
| Last trade - 14.57pm 16/09/2024 (20 minute delay) ? |
| OCC (ASX) Chart |